Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Rambus on Initiation of $100 Million Accelerated Share Repurchase Program
On June 16, 2021, Rambus Inc., a provider of industry-leading chips and silicon IP making data faster and safer, announced that it initiated an accelerated share repurchase program with Deutsche Bank AG, London Branch as counterparty, through its agent Deutsche Bank Securities Inc. (Deutsche Bank) to repurchase an aggregate of approximately $100 million of its common stock. Wilson Sonsini Goodrich & Rosati represented Rambus in the transaction.
Client Highlights
Wilson Sonsini Advises Rambus on Acquisition of PLDA
On June 16, 2021, Rambus Inc., a provider of industry-leading chips and silicon IP making data faster and safer, announced it has signed an agreement to acquire PLDA, an industry leader in Compute Express Link (CXL) and PCI Express (PCIe) digital solutions. Wilson Sonsini Goodrich & Rosati represented Rambus in the transaction with the assistance of TaylorWessing with regards to French law matters.
Client Highlights
Wilson Sonsini Advises Rambus on Acquisition of AnalogX
On June 16, 2021, Rambus Inc., a provider of industry-leading chips and silicon IP making data faster and safer, announced it has signed an agreement to acquire AnalogX, the leading provider of low power multi-standard connectivity SerDes IP solutions. Wilson Sonsini Goodrich & Rosati advised Rambus on the transaction with the assistance of Faskin regarding Canadian law matters.
Client Highlights
Firm Advises Verve Therapeutics on IP Matters Related to $266.7 Million IPO
On June 16, 2021, Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of the shares are being offered by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to an additional 2,105,368 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market on June 17, 2021, under the ticker symbol “VERV.” The offering is expected to close on June 21, 2021, subject to the satisfaction of customary closing conditions.
Client Highlights
Wilson Sonsini Advises Circle Pharma on $66 Million Series C Financing
On June 16, 2021, Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $66 million in an oversubscribed Series C financing. The financing was co-led by The Column Group and Nextech Invest. All investors from the prior round participated in the Series C, including Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati represented Circle Pharma in the transaction.
The Life Sciences Report - Q1 2021
In this issue, we feature articles on managing IP development and capture at growing medtech start-ups, life sciences venture financings in which firm clients participated during 2020, the U.S.-Japan Healthcare Connection's virtual conference on the coming revolution in healthcare, and the Biden administration's signing of two bipartisan bills that aim to promote drug competition and reduce prescription drug prices, as well as a summary of select recent life sciences client highlights.